Impact of Macrophage Inflammatory Protein-1α Deficiency on Atherosclerotic Lesion Formation, Hepatic Steatosis, and Adipose Tissue Expansion by Kennedy, Arion et al.
Impact of Macrophage Inflammatory Protein-1a
Deficiency on Atherosclerotic Lesion Formation, Hepatic
Steatosis, and Adipose Tissue Expansion
Arion Kennedy
., Marnie L. Gruen
., Dario A. Gutierrez, Bonnie K. Surmi, Jeb S. Orr, Corey D. Webb,
Alyssa H. Hasty*
Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
Abstract
Macrophage inflammatory protein-1a (CCL3) plays a well-known role in infectious and viral diseases; however, its
contribution to atherosclerotic lesion formation and lipid metabolism has not been determined. Low density lipoprotein
receptor deficient (LDLR
2/2) mice were transplanted with bone marrow from CCL3
2/2 or C57BL/6 wild type donors. After 6
and 12 weeks on western diet (WD), recipients of CCL3
2/2 marrow demonstrated lower plasma cholesterol and triglyceride
concentrations compared to recipients of C57BL/6 marrow. Atherosclerotic lesion area was significantly lower in female
CCL3
2/2 recipients after 6 weeks and in male CCL3
2/2 recipients after 12 weeks of WD feeding (P,0.05). Surprisingly, male
CCL3
2/2 recipients had a 50% decrease in adipose tissue mass after WD-feeding, and plasma insulin, and leptin levels were
also significantly lower. These results were specific to CCL3, as LDLR
2/2 recipients of monocyte chemoattractant protein
2/2
(CCL2) marrow were not protected from the metabolic consequences of high fat feeding. Despite these improvements in
LDLR
2/2 recipients of CCL3
2/2 marrow in the bone marrow transplantation (BMT) model, double knockout mice, globally
deficient in both proteins, did not have decreased body weight, plasma lipids, or atherosclerosis compared with LDLR
2/2
controls. Finally, there were no differences in myeloid progenitors or leukocyte populations, indicating that changes in body
weight and plasma lipids in CCL3
2/2 recipients was not due to differences in hematopoiesis. Taken together, these data
implicate a role for CCL3 in lipid metabolism in hyperlipidemic mice following hematopoietic reconstitution.
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Introduction
Atherosclerotic lesion formation is a multifaceted disease
process, and immune cell infiltration into the artery wall is an
essential component of lesion growth. Macrophages are one of the
predominant cell types that are recruited to the artery wall;
however, other immune cells such as T-cells and neutrophils can
also enter atherosclerotic lesions. Many different factors contribute
to leukocyte recruitment to the artery wall and the best understood
are chemoattractant cytokines called chemokines. Chemokines are
8–10 kDa proteins that bind to receptors such as the CC and
CXC family of G-protein coupled receptors. One of the most
potent macrophage chemokines is monocyte chemoattractant
protein 21 (CCL2). Mice with a global deletion of CCL2 or its
receptor, CCR2, demonstrate protection from atherosclerotic
lesion formation [1,2,3].
Another chemokine, macrophage inflammatory protein-1a,
CCL3 in standard nomenclature, has been shown to be increased
in the aortas of apolipoprotein E deficient (apoE
2/2) mice [4] and
in human carotid endarterectomy samples [5]. It is a member of
the CC chemokine family and found in the same subfamily as
CCL4, CCL5, and CCL15. Like most chemokines, CCL3 is a
chemoattractant for several different leukocytes, with varying
degrees of potency (monocytes=T-cells.neutrophils.eosino-
phils). CCL3 expression is inducible in most mature hematopoietic
cells by LPS, viral infection, and TNFa [6,7]. Our laboratory has
also shown that macrophage CCL3 expression is dramatically
induced by incubation with VLDL [8]. Thus, CCL3 may impact
atherosclerotic lesion formation via several different mechanisms.
Despite the known importance of chemokines in atherosclerotic
lesion formation and the extensive literature on CCL2, little is
known regarding the role of CCL3 in atherosclerosis or in other
metabolic processes. Hyperlipidemia is positively associated with
the production of CCL3 in a various mouse models of
atherosclerosis and obesity [9,10,11]. Similarly, CCL3 has been
shown to be elevated in the plasma and metabolic tissues (liver and
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disease [12,13]. Based on these associations and the function of
CCL3, it is possible that under hyperlipidemic conditions, CCL3 is
an important chemokine in recruitment of immune cells to
atherosclerotic lesions and other metabolic tissues.
In this study, we sought to determine whether absence of CCL3
expression could protect against atherosclerotic lesion formation in
LDLR
2/2 mice. To this end, we performed bone marrow
transplantation (BMT) studies in LDLR
2/2 recipient mice and
also developed CCL3
2/2;LDLR
2/2 double knockout mice. Our
findings demonstrate that hematopoietic CCL3 plays a role in
atherosclerotic lesion formation by regulating lipid metabolism.
Results
STUDY 1
Plasma lipids and insulin concentrations are lower in
CCL3
2/2RLDLR
2/2 mice. Male and female LDLR
2/2 mice
were lethally irradiated and transplanted with bone marrow from
C57BL/6 or CCL3
2/2 donor mice. At 4 weeks post-BMT, mice
were placed on WD for 6 or 12 weeks (Study #1 in Figure S1). No
differences in total cholesterol (TC) or triglyceride (TG) levels
between the two transplant recipient groups were observed before
transplantation (Table 1), although non esterified fatty acid
(NEFA) levels were higher in recipients of CCL3
2/2 marrow.
After 6 weeks of WD feeding, plasma TC and TG were increased
from baseline in all mice. However, in both male and female mice,
the recipients of CCL3
2/2 marrow had significantly lower TC
(22–24%, P,0.01), TG (32–38%, P,0.001), and NEFA (19–20%,
P,0.05) compared to the C57BL/6 recipients. Plasma insulin
levels were also lower in male CCL3
2/2RLDLR
2/2 mice (50%,
P,0.0005). A glucose tolerance test in a subset of mice did not
reveal improvements in glucose tolerance, although plasma insulin
levels trended to be reduced 30 min after administration of the
glucose bolus (Figure S2). By 12 weeks post-WD feeding, TC and
TG remained significantly lower in the female CCL3
2/2
RLDLR
2/2 mice compared to the C57BL/6RLDLR
2/2
controls and in male mice, there was a trend for a reduction in
TGs and NEFAs. FPLC analysis revealed that the reduction in
plasma lipids were due to modest decreases in VLDL and LDL
cholesterol (Figure S3).
Atherosclerotic lesion area is reduced in CCL3
2/2
RLDLR
2/2 mice. Atherosclerotic lesion area was measured
from ORO-stained sections in the aortic root of mice fed the WD
for 6 and 12 weeks (Figs. 1 and 2).For both time points, female mice
had larger lesions than male mice. After 6 weeks of WD feeding,
Table 1. Plasma parameters in CCL3
2/2RLDLR
2/2 mice.
Donor Marrow n TC (mg/dL) TG (mg/dL) NEFA (mEq/L) Insulin (ng/mL) Leptin (ng/mL)
Baseline
Male
C57BL/6 28 125649 2 64 0.8960.06 N/D N/D
CCL3
2/2 27 128649 9 66 1.2960.08
I N/D N/D
Female
C57BL/6 18 149698 1 66 1.0460.10 N/D N/D
CCL3
2/2 21 134677 9 64 1.1160.09 N/D N/D
6 weeks post-WD
Male
C57BL/6 15 793633 270618 0.9160.05 0.7260.05 8.9660.85
CCL3
2/2 14 624647
{ 167611
# 0.7460.05* 0.4160.05
I 4.4560.58
I
Female
C57BL/6 11 833633 236612 0.8660.04 0.5460.05 9.0561.68
CCL3
2/2 12 639643
{ 160615
1 0.6960.03
{ 0.4260.05 5.7061.49
12 weeks post-WD
Male
C57BL/6 13 634634 364658 1.3960.14 0.9060.08 17.7562.75
CCL3
2/2 13 587634 278634 1.1160.86 0.7060.07 7.4561.69
{
Female
C57BL/6 7 687641 227614 1.0560.09 0.7160.07 11.2862.27
CCL3
2/2 95 0 8 632
{ 160612
{ 0.9760.11 0.6960.06 7.2661.46
LDLR
2/2 mice were transplanted with C57BL/6 or CCL3
2/2 bone marrow. At 4 weeks post-BMT, mice were placed on WD for either 6 or 12 weeks. Blood was collected
for plasma analysis before transplantation (baseline) and at 6 and 12 weeks post-WD. For baseline plasma analysis, values were not different between the two transplant
groups; thus, these cohorts are combined in the table. Six week and 12 week values represent only the mice sacrificed at that time point. Data are the mean 6 SEM. N/
D=not determined.
*P,0.05.
{P,0.01.
{P,0.005.
1P,0.001.
IP,0.0005.
#P,0.00001.
doi:10.1371/journal.pone.0031508.t001
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2/2RLDLR
2/2 mice showed a significant decrease
in lesion area compared to their controls (P,0.05; Figure 1A), while
male CCL3
2/2RLDLR
2/2 mice showed a trend toward a
reduction in aortic root lesion area compared to C57BL/6
RLDLR
2/2 controls (P=0.059; Figure 1B). A trend toward
decreased lesion area was detected in the 12 week WD fed female
recipients of CCL3
2/2 marrow compared to recipients of
C57BL/6 marrow (Figure 1C). Aortic root lesion area was
significantly reduced in male CCL3
2/2RLDLR
2/2 mice
compared to C57BL/6RLDLR
2/2 mice (P,0.05; Figure 1D).
No differences in lesion complexity (Figure 2, Trichrome stained
panels) were apparent. In addition, despite the differences in lesion
area between the two recipient groups, in all cases, nearly the entire
lesion stained positive for macrophages (Figure 2, MOMA-2
immunostained panels). Immunofluorescence staining for CD4
positive T cells demonstrated a significantly decreased number and
percent of T cells in the CCL3
2/2RLDLR
2/2 male mice
compared to controls (Figs. 2 and 3).
Body adiposity is lower in CCL3
2/2RLDLR
2/2
mice. Body weight as well as total body fat and lean mass
were measured one week pre-BMT, at 4 weeks post-BMT, and at
6 and 12 weeks post-WD (Table 2). There were no differences in
total body weight, total fat mass, or total muscle mass in female
mice between the two groups at any time point. However, in male
mice, weight gain after WD-feeding was reduced in the CCL3
2/2
RLDLR
2/2 compared to C57BL/6RLDLR
2/2 mice at each of
the three time points post-BMT (Figure 4A). This was reflected by
a decrease in muscle mass at 4 weeks post-BMT and at 6 weeks
post-WD (Figure 4B); however, the most significant difference was
seen in total body adipose tissue mass (Figure 4C) where total body
fat of the CCL3
2/2 recipients was 56% lower at 12 weeks post-
WD. At sacrifice, perigonadal fat pad mass of CCL3
2/2
RLDLR
2/2 mice was 61% lower compared to C57BL/6
RLDLR
2/2 mice (P,0.01, Table 2). In addition, plasma leptin
levels were 2.4-fold lower in the CCL3
2/2 recipients (P,0.005,
Table 1). The lower body weight and adipose tissue mass were not
due to a general wasting, as the mice appeared healthy and the
mass of other organs such as liver (Table 2) and kidney (data not
shown) were not different between the groups.
Gene expression in adipose tissue of CCL3
2/2RLDLR
2/2
mice. Because macrophage accumulation in adipose tissue is
closely associated with the degree of adiposity [14,15], and
chemokines are thought to play a role in their recruitment to
adipose tissue, we performed realtime RT-PCR analysis for
markers of macrophage gene expression in RNA isolated from
perigonadal fat pads (Figure 4D). Interestingly, CCL3 expression
was nearly undetectable in the adipose tissue of CCL3
2/2
RLDLR
2/2 mice. Expression of CCL2 was not different
between groups; however, CCL4 was significantly lower in
CCL3
2/2 recipients (P,0.01). Expression of the CCL3
Figure 1. Recipients of CCL3
2/2 bone marrow have reduced lesion area. LDLR
2/2 mice were transplanted with C57BL/6 or CCL3
2/2 bone
marrow according to the Methods section. At 4 weeks post-BMT, mice were placed on WD for 6 or 12 weeks. Aortic root lesion area was quantified
according to the Methods section. Panels A and B show lesion area from female and male mice after 6 weeks of WD feeding, respectively. Data are
presented as mean 6 SEM from 7–14 mice per group. Panels C and D show the lesion area from female and male mice after 12 weeks of WD feeding,
respectively. Data are mean 6 SEM from 7–13 mice per group.
doi:10.1371/journal.pone.0031508.g001
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transplant groups. Similarly, expression of the macrophage
markers F4/80 and CD68 and the T-cell markers CD3e and
FoxP3 were not different between the two BMT groups. To
evaluate the polarization of macrophages within the adipose tissue,
expression of M1 and M2 markers was quantified. The M1, pro-
inflammatory cytokine TNF-a was significantly reduced (P,0.05)
in CCL3
2/2 recipients. M2 markers, arginase 1, CD163,
mannose receptor C, Mgl1, and Mgl2 were not different.
Toluidine Blue O of the adipose tissue revealed no obvious
difference in adipocyte size between the two groups (Figure 4E–F).
Similar gene expression patterns were found in the adipose tissue
of female mice, although the M2 markers were significantly
reduced in the CCL3
2/2 recipients (data not shown).
Liver lipids and gene expression in CCL3
2/2RLDLR
2/2
mice. Hepatic TG content after 6 and 12 weeks of WD feeding
was reduced by about 20% in male CCL3
2/2RLDLR
2/2 mice
compared to C57BL/6RLDLR
2/2 controls (Figure 5A–B).
There were no differences in liver TG between the two female
groups (data not shown).
Expression levels of chemokines, macrophage markers, and
lipogenic genes were also assessed in the livers of BMT mice
(Figure 5C). Similar to what was found in adipose tissue, CCL3
expression was nearly undetectable in the CCL3
2/2RLDLR
2/2
livers and CCL4 expression was significantly reduced (P,0.05).
CCL5 expression was not different between recipient groups.
TNF-a expression was significantly lower in CCL3
2/2 recipients
at 6 weeks (P,0.01). In contrast to the atherosclerotic lesions, T
cell markers CD3e and FoxP3 were not different in livers between
groups.
Impact of CCL3 on hematopoietic stem cell (HSC)
progenitors and leukocytes. Due to the metabolic
Figure 2. Lesion complexity does not differ with CCL3 bone marrow genotype. LDLR
2/2 mice were transplanted with C57BL/6 or CCL3
2/2
bone marrow. At four weeks post-BMT, mice were placed on WD for 12 weeks. ORO (46), Trichrome, MOMA-2, and CD4 stained lesion (106) are in
columns as indicated on figure. Gender and donor marrow are indicated on the left of the figure. Sections were chosen from images representing
mice with lesion areas close to the mean of their respective groups.
doi:10.1371/journal.pone.0031508.g002
Figure 3. Recipients of CCL3
2/2 marrow have reduced lesional T lymphocytes. Sections from the aortic root of male and female CCL3
+/+
RLDLR
2/2 and CCL3
2/2RLDLR
2/2 mice were used for immunofluorescent analysis of CD4 positive T-cells according to the Methods section. For
each mouse, data from the three valves was combined. Total dapi stained nuclei (Panel A) and CD4 positive cells were quantified (Panel B). The
percent of cells that were CD4 T cells was calculated by dividing the total cells by the CD4 positive cells (Panel C). Data represent the mean 6 SEM of
3–6 mice per group. * P,0.01 compared to male CCL3
+/+RLDLR
2/2.
doi:10.1371/journal.pone.0031508.g003
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2/2RLDLR
2/2 mice, we sought to
determine whether absence of CCL3 influences reconstitution of
hematopoietic stem cells (HSC) and progenitor cells in the bone
marrow of LDLR
2/2 mice after BMT. It is known that injection
of CCL3 into mice inhibits progenitor cell proliferation [16];
however, mice globally deficient in CCL3 have no abnormalities
in progenitor cells or leukocytes [17]. Bone marrow cells were
collected from male recipients of C57BL/6 and CCL3
2/2 at 6
weeks post-WD and analyzed by flow cytometry for the presence
of cell markers expressed on hematopoietic stem cells (HSC) or
progenitor cells. HSC were characterized as negative for lineage
markers (Lin
2) and expressed stem cell antigen 1 (Sca-1) and c-kit
(for gating strategy, please see Figure S4). There were no
differences detected in HSC levels between groups (Figure 6A).
Next we examined progenitor cell populations in bone marrow.
HSC proliferate and differentiate into progenitor cells, such as
common myeloid progenitors (CMP), megakaryocyte/erythroid
progenitors (MEP), and granulocyte/macrophage progenitors
(GMP), which develop into mature effector cells. Progenitor cells
were identified by bone marrow cells expressing c-kit
high and
CD34 or FccII/III. There were no significant changes detected
in common myeloid progenitor (CMP; Figure 6B) cells,
megakaryocyte/erythroid progenitors (MEP; Figure 6C) or
granulocyte/macrophage progenitors (GMP; Figure 6D) between
groups.
Based on the ability of stem cells to differentiate into various cell
types (granulocytes, macrophages, dendritic cells, etc) we examined
leukocyte populations in bone marrow and blood at 5 weeks post-
BMT and blood, bone marrow, liver, and adipose tissue in mice
following 6 weeks of WD. A complete blood count revealed no
differences in leukocyte populations (Figure S5, Panel A). With
regards to gene expression on blood leukocytes, as expected, CCL3
gene expression was significantly reduced in recipients of CCL3
2/2
bone marrow (Figure S5, Panel B). However, there were no
differences in CCR1, CCR5, or CCL5 expression. Also no
differences in lymphocyte or monocyte populations in bone
marrow, liver, or adipose tissue were detected following 6 weeks
of WD (Figure S6).
STUDY 2
Metabolic parameters in CCL2
2/2RLDLR
2/2 mice. To
determine whether amelioration of hyperlipidemia and adiposity
in BMT LDLR
2/2 mice was specific to CCL3 deficiency, we
performed a second BMT study by transplanting C57BL/6,
CCL3
2/2, or CCL2
2/2 donor marrow into male LDLR
2/2
Table 2. Body and tissue weights in CCL3
2/2RLDLR
2/2 mice.
Donor Marrow n Body Weight (g)
Total Adipose
Tissue Mass (g)
Lean Tissue Mass
(g)
Perigonadal Adipose
Tissue Mass (g) Liver Mass (g)
Baseline
Male
C57BL/6 28 21.160.3 1.960.1 17.260.3 N/D N/D
CCL3
2/2 27 20.860.3 1.860.1 17.160.2 N/D N/D
Female
C57BL/6 18 17.260.3 2.260.1 13.660.3 N/D N/D
CCL3
2/2 21 16.860.3 2.060.1* 13.760.3 N/D N/D
6 weeks post-WD
Male
C57BL/6 15 24.460.6 4.260.3 17.960.4 0.6760.04 1.1060.03
CCL3
2/2 14 22.760.4 2.760.2
1 17.260.4 0.4160.03
I 0.9960.05
Female
C57BL/6 11 19.660.3 3.160.3 14.660.2 0.3560.03 1.0160.03
CCL3
2/2 12 18.560.3* 2.660.3 14.560.2 0.2560.04 0.9660.02
12 weeks post-WD
Male
C57BL/6 13 27.561.0 6.460.7 19.060.4 1.0860.11 1.2660.08
CCL3
2/2 13 24.860.5* 4.160.4
{ 18.060.3 0.6760.06
{ 1.1060.04
Female
C57BL/6 7 21.060.6 3.760.5 15.660.3 0.4460.07 1.0560.05
CCL3
2/2 9 20.660.7 3.660.4 15.560.4 0.4160.05 1.0060.05
LDLR
2/2 mice were transplanted with C57BL/6 or CCL3
2/2 bone marrow. At 4 weeks post-BMT, mice were placed on WD for either 6 or 12 weeks. Body weight as well
as total body lean and fat mass were measured at each time point. There were no differences in values between the two transplantations cohorts at baseline; thus, these
values are presented for all mice together. Six week and 12 week values represent only the mice sacrificed at that time point. Data are the mean 6 SEM. N/D=not
determined.
*P,0.05.
{P,0.01.
{P,0.005.
1P,0.0005.
IP,0.0001.
doi:10.1371/journal.pone.0031508.t002
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were placed on WD for 6 weeks. The CCL3
2/2RLDLR
2/2 mice
displayed a similar reduction in body weight, total body adipose
tissue, TC, TG, NEFA, and leptin as was seen in the original study
(Table 3). However, CCL2
2/2RLDLR
2/2 mice were not
different from C57BL/6RLDLR
2/2 mice for any parameter
tested. Differences in food intake did not account for the reduced
body weight and adiposity in CCL3
2/2RLDLR
2/2 mice,
resulting in reduced feeding efficiency in these mice (Figure S7).
STUDY 3
Body weight, lipoprotein metabolism and atherosclerosis
in CCL3
2/2;LDLR
2/2 mice. Because we detected reductions
in plasma lipids and lesion areas in the BMT model, we
investigated whether these reduction were specific to the BMT
model. To this end, we developed a double knockout model of
CCL3 and LDLR. Male littermate CCL3
+/+;LDLR
2/2, CCL3
+/
2;LDLR
2/2, and CCL3
2/2; LDLR
2/2 mice were placed on
WD at 8 wks of age and maintained on this diet for 12 weeks
(Study #3 in Figure S1). There were no differences among
genotypes in body weight throughout the study (Figure S8, Panel
A). In addition, adiposity, adipose tissue weight and liver weight
were not different between groups (Table S1). Following 12 weeks
on WD, there were no differences in plasma parameters among
the groups (Table S1). FPLC analyses of plasma cholesterol and
triglycerides revealed only modest differences between groups
(Figure S8, Panels C and D). Plasma glucose, insulin, and leptin
concentrations were unaffected by CCL3 deficiency (Table S2).
Similarly, atherosclerotic lesion area was quantified at the aortic
root and no differences based on CCL3 genotype were detected
(Figure S8, Panel B). Similar results were found for female mice
(data not shown).
Discussion
In this study, we have shown an interesting dichotomy that
deficiency of CCL3 in bone marrow-derived cells is protective
against hyperlipidemia, atherosclerosis, diet-induced obesity and
Figure 4. Adipose tissue mass and gene expression. Male LDLR
2/2 mice were transplanted with C57BL/6 or CCL3
2/2 bone marrow. At 4 weeks
post-BMT, mice were placed on WD for either 6 or 12 weeks. (A–C) Body weight, total body lean mass, and total body adipose tissue were measured
by NMR pre-BMT, 4 weeks post-BMT, and at 6 and 12 weeks post-WD. Data from pre-BMT, 4 weeks post-BMT, and 6 weeks post-WD are combined for
the 6 week and 12 week groups. The 12 week post-WD data represent only the mice sacrificed at that time point. (D–F) Perigonadal adipose tissue
was collected from the mice fed WD for 12 weeks. RNA was isolated and used for real-time RT-PCR analysis as described in the Methods section. Data
are the mean 6 SEM of the relative gene expression for 12–14 mice per group. Images are from Toluidine Blue O stained sections processed as
described in the Methods section. * P,0.05 ** P,0.01 *** P,0.0005 CCL2=monocyte chemoattractant protein-1 TNF-a=tumor necrosis factor-a
Man Rec C=mannose receptor C Mgl=macrophage galactose N-acetyl-galactosamine specific lectin.
doi:10.1371/journal.pone.0031508.g004
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2/2
mice seems to have little impact on these metabolic processes.
Furthermore, transplantation of LDLR
2/2 mice with CCL2
2/2
marrow does not recapitulate the effects of CCL3. Combined, these
data suggest that CCL3 influences bone marrow reconstitution in
ways that ultimately impact lipid metabolism in hyperlipidemic
mice.Inanefforttodeterminemechanismsbywhichthisoccurs,we
analyzed bone marrow progenitor stem cell lineages, circulating,
and tissue specific immune cell populations. However, CCL3
deficiency did not impact any of these immune cell populations.
Taken together these data provide evidence that CCL3 may be an
important link in metabolic processes associated with hyperlipide-
mia; however, the mechanism by which this occurs is not
clear.
The primary endpoint of our study was atherosclerotic lesion
formation. Previous studies have demonstrated the presence of
CCL3 in both mouse and human atherosclerotic lesions [4,5,18];
however, a direct role of CCL3 in atherosclerotic lesion formation
has not yet been demonstrated. We detected significant reductions
in aortic root lesion area in the CCL3
2/2RLDLR
2/2 compared
to C57BL/6RLDLR
2/2 mice (Figure 1). The protection from
lesion formation in the CCL3
2/2RLDLR
2/2 mice is likely due
to the reduced plasma lipids, especially because CCL3
2/2;
LDLR
2/2 mice did not have differences in plasma lipids or
atherosclerosis compared to CCL3
+/+;LDLR
2/2 mice. The two
receptors for CCL3 are CCR1 and CCR5. CCR5
2/2 mice are
protected against atherosclerosis [19,20,21] while CCR1
2/2 mice
have accelerated lesion formation [20,22]. Notably, expression of
CCR1 and CCR5 were not different on leukocytes from CCL3
2/2
RLDLR
2/2 compared to CCL3
+/+;LDLR
2/2 mice (Figure S5,
Panel B). Thus, absence of a ligand that activates both of these
receptors may offset the pro- and anti-atherogenic effects of each.
The observation that deficiency of bone marrow-derived CCL3
leads to a reduction of plasma lipids is a salient finding, although
the mechanisms by which this occurs are unclear. A role for
chemokines in modulating lipid levels has not been previously
reported. For example, changes in CCL2 expression via global
knockout or transgenic over-expression do not influence plasma
lipid levels [2,23]. Likewise, deficiency of chemokine receptors
CCR1, CCR2, and CCR5 in mice have not been shown to
influence lipoprotein metabolism [19,20,22,24,25]. However,
there is ample evidence that the converse is biologically significant,
i.e., lipid levels can modulate chemokine expression. We have
previously shown that exposure of macrophages to VLDL induces
a 5-fold increase in CCL3 gene expression in vitro [8]. Human
studies also support the notion that CCL3 expression and secretion
can be modulated by lipids. In studies of patients with familial
hypercholesterolemia, Holven et al. have shown that peripheral
blood mononuclear cells (PBMCs) from hypercholesterolemic
patients had enhanced CCL3, CCL4, and IL-8 expression
compared to normolipidemic controls and that release of these
chemokines correlated positively with plasma cholesterol levels
[26]. This data is supported by the observations of Wahre et al. that
patients with coronary artery disease had dramatic increases in
PBMC chemokine and chemokine receptor expression levels
[27,28], and that the elevated expression was blunted following
treatment with statins [27]. Even more interesting, Funk and
colleagues made the observation that among 18 inflammatory
cytokines and chemokines analyzed, CCL3 was the only one to be
consistently increased in plasma of hyperlipidemic mice [10]. The
improvements in plasma lipids might be explained by the reduced
hepatic steatosis in recipients of CCL3
2/2 bone marrow. It has
previously been shown that CCL2 and CCL3 expression are
increased in human steatotic livers [12]. Similarly, plasma CCL3
Figure 5. Lipid accumulation and gene expression in liver. Liver was collected from the male mice fed WD for 6 or 12 weeks. (A–B) Liver TG
was quantified by GC-MS as described in the Methods section. (C) RNA was isolated and used for real-time RT-PCR analysis as described in the
Methods section. Data are the mean 6 SEM of the relative gene expression for 8–12 mice per group. CCL2=monocyte chemoattractant protein-1
TNF-a=tumor necrosis factor-a SREBP-1c=sterol regulatory element binding protein-1c * P,0.05 ** P,0.01 *** P,0.001.
doi:10.1371/journal.pone.0031508.g005
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Finally, studies by Wouters et al. demonstrated an 11-fold increase
in hepatic CCL3 expression in WD-fed LDLR
2/2 mice whereas
C57BL/6 mice had only a 3-fold increase [9]. Thus, it is possible
that CCL3 and hyperlipidemia are mechanistically linked.
Hyperlipidemia induces profound effects on immune cell
homeostatsis, by enhancing hematopoiesis, monocytosis, and
neutrophilia [30,31,32]. An alternative to the concept that
CCL3 directly influences lipoprotein metabolism is that it
indirectly influences lipid homeostasis by modulation of hemato-
poiesis. It is possible that chemokines within the bone marrow may
mediate some of the effects of hyperlipidemia on hematopoiesis In
fact, a role for CCL3 in bone marrow myeloid progenitor cell
colony formation has been shown in vitro, whereby, CCL3
enhances the myelopoietic activity of mature progenitors but
suppresses the myelopoietic activity of immature progenitors [33].
Although global CCL3
2/2 mice were reported to have normal
hematopoiesis and leukocyte populations [17]; the ability of these
cells to proliferate rapidly to reconstitute a lethally irradiated
hyperlipidemic mouse had not been determined. Our studies
demonstrate that stem cell lineages were not altered in the bone
marrow of CCL3
2/2 recipients at 6 weeks post-WD. Thus,
changes in hematopoiesis following BMT are not likely to be the
explanation for the reduced plasma lipid levels and body weight in
the CCL3
2/2RLDLR
2/2 mice.
Our laboratory is interested in macrophage infiltration not only
into the artery wall, but also into adipose tissue. Based on analysis
of macrophage markers such as CD68 and F4/80 and
inflammatory markers such as TNFa, CCL3
2/2RLDLR
2/2
adipose tissue had only slightly lower macrophage content
Table 3. Plasma parameters in C67BL/6RLDLR
2/2, CCL3
2/2RLDLR
2/2, and CCL2
2/2RLDLR
2/2 mice at 6 weeks post WD-
feeding.
Genotype n Body weight (g)
Total Body
adipose tissue (g) TC (mg/dL) TG (mg/dL) NEFA (mEq/L) Insulin (ng/mL) Leptin (ng/mL)
C57BL/6RLDLR
2/2 7 24.160.7 3.0460.38 723664 263631 0.8260.05 0.6460.13 9.462.1
CCL3
2/2RLDLR
2/2 6 22.260.8 2.506.032 517655 155619 0.6260.09 0.6860.12 6.161.5
CCL2
2/2RLDLR
2/2 7 24.261.0 3.1960.43 7986103 244639 0.7460.07 0.5560.08 9.662.1
Male LDLR
2/2 mice were transplanted with C57BL/6, CCL3
2/2 or CCL2
2/2 bone marrow. At 4 weeks post-BMT, mice were placed on WD for 6 weeks. Data are the mean
6 SEM of 6–7 mice per group.
doi:10.1371/journal.pone.0031508.t003
Figure 6. Stem cell progenitors in CCL3
2/2RLDLR
2/2 mice. Male LDLR
2/2 mice were transplanted with C57BL/6 or CCL3
2/2 bone marrow. At
6 weeks post-WD, bone marrow cells were collected and analyzed by flow cytometry. (A) Quantification of flow cytometry analysis of HSC cells which
were identified as lineage negative (Lin
2) and expressing high levels of c-kit and Sca-1 (Lin
2c-kit
highSca-1
+). (B) CMP cells were identified as Lin
2c-
kit
highCD34
+FccRII/III
lo. (C) MEP cells were defined as Lin
2c-kit
highCD34
2FccRII/III
lo. (D) GMP cells were defined as Lin
2c-kit
highCD34
+FccRII/III
high. Data
represent the mean6 SEM of 5–6 mice per group. *P,0.05 compared to C57BL/6
2/2 groups.
doi:10.1371/journal.pone.0031508.g006
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2/2 recipients. In fact, other data
from our laboratory shows that even global deficiency of CCL3
does not reduce adipose tissue macrophage numbers [34]. This
was unexpected given CCL3 is highly expressed in adipose tissue
[14,15,35], and is a potent chemoattractant molecule. Although
chemokines have been proposed to be primarily responsible for
macrophage recruitment to adipose tissue, and some evidence
exists that CCL2 and its receptor, CCR2, contribute to adipose
tissue macrophage content [36,37], conflicting reports have also
been published [38,39,40]. We also found that CCL4 expression
was significantly reduced in CCL3
2/2RLDLR
2/2 mice. Thus,
the CCL3
2/2RLDLR
2/2 mice were effectively deficient in
adipose tissue expression of CCL3 and CCL4, and yet adipose
tissue macrophage recruitment was not affected. Many studies,
including our current report, support a role for individual
chemokines in macrophage recruitment to atherosclerotic lesions;
however, their role in macrophage recruitment to adipose tissue is
more subtle, suggesting more extensive overlap of chemokine
function with regards to macrophage recruitment to adipose tissue.
In conclusion, our current data demonstrate reduced body
weight, hepatic steatosis, and plasma insulin levels in CCL3
2/2
RLDLR
2/2 compared to C57BL/6RLDLR
2/2 mice. This
metabolic impact of CCL3 deficiency following BMT is unique to
CCL3 as recipients of CCL2
2/2 marrow did not show the same
phenotype. Furthermore, CCL3 deficiency did not impact on lipid
metabolism in the double knockout mouse model (CCL3
2/2;
LDLR
2/2). Although we detected no differences in bone marrow
hematopoietic precursors or circulating leukocyte populations
following BMT, our combined data point to a role for CCL3 in
metabolism following bone marrow reconstitution of hyperlipid-
emic LDLR
2/2 mice.
Materials and Methods
Mice
All animal care procedures were performed in accordance with
and approval by the Vanderbilt University Institutional Animal
Care and Use Committee (approval # M06/476). C57BL/6,
LDLR
2/2, CCL3
2/2, and CCL2
2/2 mice were originally
purchased from Jackson Laboratories (Bar Harbor, ME) and were
propagated within our colony to produce the donor and recipient
mice used in this study. All mice were on the C57BL/6
background. Study 1: At 8 weeks of age, mice were lethally
irradiated with 900 rads from a Cesium gamma source and
transplanted with marrow from C57BL/6 or CCL3
2/2 marrow
collected from the long bones of donor mice. Hereafter, these
groups will be referred to as C57BL/6RLDLR
2/2 and CCL3
2/2
RLDLR
2/2. Recipient mice were given water containing 0.25%
neomycin/polymyxin B sulfate (Monarch Pharmaceuticals, Bristol,
TN) for 1 week prior to and 2 weeks following bone marrow
transplantation (BMT). Four weeks post-BMT, mice were ad libitum
fed Western diet (WD) which contains 42% of kcal from milk fat
with 0.15% cholesterol added (Harlan-Teklad, Madison, WI) for 6
or 12 weeks (for study design, please see Figure S1). Study 2: Male
LDLR
2/2 mice were transplanted with bone marrow from
C57BL/6, CCL3
2/2 or CCL2
2/2 donors and placed on the
WD for 6 weeks. These groups are designated as C57BL/
6RLDLR
2/2, CCL3
2/2RLDLR
2/2 and CCL2
2/2
RLDLR
2/2. Study 3: CCL3
2/2 and LDLR
2/2 mice were
crossed to generate CCL3
+/2;LDLR
+/2 mice, which were then
bred to generate littermate CCL3
+/+;LDLR
2/2, CCL3
+/2;
LDLR
2/2, and CCL3
2/2;LDLR
2/2 mice. At the end of each
study, mice were fasted for 5 h, bled via the retro-orbital plexus,
perfused with PBS, and tissues collected. Blood was centrifuged,
plasma collected, and frozen. Blood was also used for DNA analysis
to confirm the complete reconstitution of the BMT mice with donor
bone marrow (data not shown).
Food intake
Mice were housed 2–3 mice per cage, and the weight of the food
remaining in the cage was quantified 2 times per week. The
average daily food intake per mouse was calculated based on the
number of mice per cage and the difference between the starting
and ending food weights. Feeding efficiency was calculated by
taking the average weight gain in mg/average daily caloric intake.
Plasma analyses
Total plasma cholesterol (TC) and triglyceride (TG) levels were
measured using enzymatic assays from Cliniqa Inc. (San Diego,
CA). Very low-density lipoprotein (VLDL), low-density lipoprotein
(LDL), and high-density lipoprotein (HDL) were measured by
using fast performance liquid chromatography (FPLC) as de-
scribed [41]. Non-esterified fatty acids (NEFAs) were measured
using the NEFA-HR 2 kit from Wako (Richmond, VA). Insulin
and leptin levels were measured by RIA in the Hormone Assay
Core Laboratory of the Vanderbilt Mouse Metabolic Phenotyping
Center (MMPC).
Body composition analysis
Mice were analyzed for total body adipose tissue and lean body
mass before transplantation, 4 weeks post-BMT (before starting
WD feeding), 6 weeks-post WD, and 12 weeks post-WD. These
analyses were performed by nuclear magnetic resonance using the
Bruker Minispec (Woodlands, TX) at the Vanderbilt University
MMPC.
Atherosclerotic lesion formation
At sacrifice, hearts from all mice were placed in OCT and
frozen on dry ice. Hearts were cut according to the method of
Paigen et al. [42] and 15 sections extending from the aortic root for
300 mm were collected. Sections were stained with Oil Red O
(ORO), images captured using a Q-imaging Micropublisher
camera mounted on an Olympus upright microscope, and the
stained area quantified using Histometrix 6 software by Kinetic
Imaging, Ltd. (Durham, NC).
Immunohistochemical Analysis
Five mm aortic root sections were stained for MOMA using 1:50
dilution of rat anti-mouse macrophage antibody from Serotec
(Raleigh, NC). Briefly, sections were in cold acetone and washed
with PBS. Sections were then blocked in 2% BSA/PBS for
30 min. A 15 min avidin/biotin block (SP-2001 Vector Labora-
tories Burlingame, CA) was performed. For CD4 immunofluores-
cence, rat anti-mouse CD4 primary antibody (BD Biosciences, San
Jose, CA) was applied at 1:20 dilution for 1 h, slides were washed
with PBS and secondary antibody (biotinylated goat anti-rat IgG)
was applied at 1:100 for 30 min at 37uC. Strepavidin- Texas Red
(A-2006 Vector Laboratories Burlingame, CA) was applied at
10 mg/ml in 2% BSA/PBS for 30 min and washed with PBS.
Vectorshield (H-1200 Vector Laboratories, Burlingame, CA) was
added and slides were coverslipped.
RNA isolation and realtime RT-PCR
RNA was isolated from 100 mg of perigonadal adipose tissue
using the RNeasy minikit from Qiagen (Valencia, CA). cDNA was
synthesized using the iScript cDNA synthesis kit from BioRad
(Hercules, CA). cDNA was diluted 1:5 or 1:10 and then used for
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sets were purchased from the ‘‘Assays-on-Demand’’ program from
Applied Biosystems (Foster City, CA). Quantification of 18S was
performed for each sample, and final relative concentration was
determined by comparing each gene of interest to 18S using the
delta delta CT method [43].
Adipose tissue histochemistry
Perigonadal adipose tissue was fixed in 10% formalin overnight
and then embedded in paraffin. Paraffin sections were fixed and
stained with Toluidine Blue O (TBO) according to manufacturer’s
instructions (Newcomer Supply, Middleton, WI).
Flow Cytometry
Cells isolated from various tissue were first incubated with
Fc block for 5 min at room temperature, followed by
incubation for 20 min at 4uC with fluorophore conjugated
antibodies: F4/80-APC (eBioscience), Ly6C-FITC (BD Biosci-
ences), CD11b-APC-Cy7 (BD Bioscience), Ly6G-PE (BD
Bioscience), Lineage marker-Alexa488 (Molecular Probes),
FccRII/III-PE-Cy7 (BD Bioscience), CD34-Alexa647 (BD
Bioscience), Sca-1-Pacific Blue (BioLegend), and c-kit-PE
(eBiosciences). Samples were processed on a 5 Laser LSRII
machine in the Vanderbilt Flow Cytometry Core and data
analyzed using FlowJo software.
Statistical analysis
Comparisons between recipients of C57BL/6 and CCL3
2/2
mice at each time point were performed using un-paired Student’s
t-tests. Comparisons among C67BL/6RLDLR
2/2, CCL3
2/2
RLDLR
2/2, and CCL2
2/2RLDLR
2/2 transplant groups were
performed using one-way ANOVA with a Tukey post-hoc test.
Comparisons among CCL3
+/+;LDLR
2/2, CCL3
+/2;LDLR
2/2,
and CCL3
2/2;LDLR
2/2 groups were also performed using one-
way ANOVA with a Tukey post-hoc test.
Supporting Information
Figure S1 Experimental Design. Study #1: Eight week old
male and female LDLR
2/2 mice were lethally irradiated and
reconstituted with bone marrow collected from C57BL/6 or
CCL3
2/2 donors. Two separate cohorts were transplanted 6
weeks apart and placed on WD for either 6 or 12 weeks starting 4
weeks after their respective transplantations. Study #2: Eight
week old male LDLR
2/2 mice were lethally irradiated and
reconstituted with bone marrow collected from C57BL/6,
CCL3
2/2 or MCP-1
2/2 donors. Four weeks after transplanta-
tion, mice were fed WD for 6 weeks. Study #3: Eight week old
littermate CCL3
+/+;LDLR
2/2, CCL3
+/2;LDLR
2/2, and
CCL3
2/2;LDLR
2/2 were placed on WD for 12 weeks.
(TIF)
Figure S2 Glucose tolerance test and plasma insulin
levels. LDLR
2/2 mice were transplanted with C57BL/6 or
CCL3
2/2 bone marrow. At four weeks post-BMT, mice were
placed on WD for 6 weeks. (A) Mice were fasted for 5 h and basal
blood glucose levels were measured (0 min) before intraperitoneal
administration of 1.5 g glucose per kg lean body mass. Blood
glucose was assessed at 15, 30, 45, 60, 90, and 150 min after
injection. (B) Plasma insulin levels were measured 30 min after
administration of the glucose bolus. Data are the mean 6 SEM of
3–6 mice per group.
(TIF)
FigureS3 FPLC analysisoflipoproteinprofiles. LDLR
2/2
mice were transplanted with C57BL/6 or CCL3
2/2 bone marrow.
At four weeks post-BMT, mice were placed on WD for 6 or 12
weeks. Plasma lipids were fractionated and cholesterol quantified as
described in the Methods section. A) females at 6 weeks post-WD; B)
males at 6 weeks post-WD; C) females at 12 weeks post-WD; D)
males at 12 weeks post-WD.
(TIF)
Figure S4 Gating strategy for bone marrow HSC and
progenitor cells. LDLR
2/2 mice were transplanted with
C57BL/6 or CCL3
2/2 bone marrow. At 5 weeks post-BMT,
bone marrrow cells were collected from recipient mice and
analyzed by flow cytometry. A) HSC cells were identified as
lineage negative cells (Lin
2) cells and expression of Sca-1 and c-kit
(Lin
2c
2kit
highSca-1
+). B) Plot of progenitor cells from C57BL/6
bone marrow cells were identified by expressing c-kit
highSca-1
2
and CD34 or FccRII/III. CMP cells were defined as Lin
2c-
kit
highCD34
+FccRII/III
lo. MEP cells were defined as Lin
2c-
kit
highCD34
2FccRII/III
lo. GMP cells were defined as Lin
2c-
kit
highCD34
+FccRII/III
high. C)PlotofprogenitorcellsinCCL3
2/2
bone marrow cells. Data presented are representative plots of the
gating strategy for HSC and progenitor cells.
(TIF)
Figure S5 Complete blood counts and gene expression.
LDLR
2/2 mice were transplanted with C57BL/6 or CCL3
2/2
bone marrow. At four weeks post-BMT, mice were placed on WD
for 6 weeks. A) Blood was collected and a complete blood cell was
performed. NE=Neutrophils, LY=Lymphocytes, MO=mono-
cytes, EO=Eosinophils, BA=Basophils. B) Leukocytes were
collected from blood and RNA was isolated and analyzed by
real-time PCR as described in the Methods section. Data are the
mean 6 SEM of the relative gene expression for 3–6 mice per
group.
(TIF)
Figure S6 Leukocyte populations in adipose tissue,
bone marrow, and liver. LDLR
2/2 mice were transplanted
with C57BL/6 or CCL3
2/2 bone marrow. At 6 weeks post-BMT
cells were collected from adipose tissue, bone marrow, and liver.
Cells were then analyzed by flow cytometry. A–B) Adipose tissue T
cells and macrophages; C–D) Bone marrow monocytes and
neutrophils; E–F) Liver T cells and monocytes. T cells were
identified by expressing TCRb. Macrophages were identified by
expressing CD11b
+F4/80
+. Monocytes were identified by express-
ing CD11b
+Ly6C
+Ly6G
2. Neutrophils were identified by ex-
pressing CD11b
+Ly6C
+Ly6G
+. Data are the mean 6 SEM of 3–6
mice per group.
(TIF)
Figure S7 Food intake and feeding efficiency. Daily food
intake and feeding efficiency were quantified for the mice in Study
#2 according to the Methods section. Data are the mean 6 SEM
of 6–7 mice per group.
(TIF)
Figure S8 Body weight, atherosclerosis, and plasma
lipoprotein profiles in CCL3
2/2;LDLR
2/2 mice. Male
CCL3
2/2;LDLR
2/2 were started on WD at 8 weeks of age and
maintained on the diet for 12 weeks. A) Body mass during WD
feeding. B) Aortic root lesion quantification at 12 weeks post-WD.
Data are from 5–8 mice per group. C and D) FPLC analysis of
lipoprotein profiles of mice at 12 weeks post WD-feeding. Plasma
lipids were fractionated and cholesterol (C) and triglycerides (D)
were quantified as described in the Methods section.
(TIF)
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Western diet feeding. CCL3
+/+;LDLR
2/2, CCL3
+/2;
LDLR
2/2, and CCL3
2/2;LDLR
2/2 mice were placed on WD
for 12 weeks. Body weight as well as total body lean and fat mass
and liver mass were measured. Data are the mean 6 SEM from
the number of mice indicated.
(DOC)
Table S2 Plasma parameters in CCL3
+/+;LDLR
2/2,i n
CCL3
+/2;LDLR
2/2, and CCL3
2/2;LDLR
2/2, after 12
weeks of Western diet feeding. CCL3
+/+;LDLR
2/2,
CCL3
+/2;LDLR
2/2, and CCL3
2/2;LDLR
2/2 mice were
placed on WD for 12 weeks. Plasma parameters were measured
from blood collected as described in the Methods section. Data are
the mean 6 SEM from the number of mice indicated.
(DOCX)
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